Doctors Revision

Antiparkinsonism Drugs: Pharmacology, Dosing and Safe Management of Parkinson Disease

Text size
On this page

1 Overview

Parkinson disease (PD) is a progressive neurodegenerative disorder of dopaminergic neurons in the substantia nigra pars compacta with intraneuronal α-synuclein (Lewy body) accumulation. Its pharmacology is rational and therefore memorable: restore striatal dopamine, or rebalance the dopamine–acetylcholine imbalance its loss creates. No drug slows the disease — all treatment is symptomatic — so therapy is a lifelong exercise in matching drugs to function, age and side-effect tolerance. All antiparkinsonian drugs are symptomatic; levodopa is the most effective and the reference against which others are measured.

2 Learning Objectives

  • Explain why levodopa (not dopamine) is given, and why carbidopa is combined with it.
  • Compare the mechanism, uses and adverse effects of dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine and anticholinergics.
  • Describe wearing-off, dyskinesias and the "on-off" phenomenon, and their management.
  • Apply safe prescribing principles: never stop levodopa abruptly, titrate slowly, watch for impulse-control disorders and psychosis.
  • Recognise drug-induced parkinsonism and its management.

3 Pathophysiology Rationale for Drug Action

The nigrostriatal pathway normally delivers dopamine to the striatum to facilitate movement. When ~60–80% of substantia nigra neurons are lost, striatal dopamine falls and the direct (movement-facilitating) pathway is under-driven while the indirect pathway is over-active — producing the cardinal features: bradykinesia (obligatory), resting tremor, rigidity and postural instability. Two pharmacological corollaries follow: (1) replacing or mimicking dopamine treats bradykinesia and rigidity best (tremor responds least); (2) with dopamine low, the cholinergic system is relatively over-active, so anticholinergics help mainly tremor and rigidity — and are hazardous in the elderly, whose cholinergic reserve is already low.

4 Levodopa & Carbidopa — the Gold Standard

  • Why levodopa — dopamine itself cannot cross the blood–brain barrier; its amino-acid precursor levodopa crosses via the LAT1 transporter and is decarboxylated to dopamine in surviving neurons and glia.
  • Why carbidopa — peripheral dopa-decarboxylase converts most levodopa to dopamine before it reaches the brain, causing nausea, vomiting, tachycardia and hypotension. Carbidopa blocks this conversion peripherally (it does not cross the BBB), increasing CNS delivery 4–5-fold and abolishing most peripheral effects. Benserazide does the same in other markets.
  • Dosing — start low, e.g. carbidopa/levodopa 25/100 mg half to one tablet 2–3 times daily; titrate to effect. Modified-release forms smooth "wearing off"; intestinal gel and rotigotine patch exist for advanced disease.
  • Adverse effects — early: nausea, hypotension, somnolence (including sudden sleep attacks). Later: motor fluctuations and dyskinesias (see below); psychiatric effects — hallucinations, impulse-control problems, psychosis at higher doses.
  • Critical safety rule — never stop levodopa abruptly: sudden withdrawal can precipitate a parkinsonism-hyperpyrexia (neuroleptic malignant–like) syndrome with rigidity, fever, autonomic instability and rhabdomyolysis. If it must stop (e.g. severe psychosis), taper and substitute another agent.

5 Other Drug Classes

Dopamine receptor agonists

Pramipexole, ropinirole, rotigotine (non-ergot) and bromocriptine, cabergoline (ergot) stimulate striatal D2/D3 receptors directly. Used as monotherapy in younger patients to delay levodopa and its dyskinesias, and as add-on later. Key adverse effects: nausea, orthostatic hypotension, sudden sleep attacks, and — uniquely important — impulse-control disorders (pathological gambling, hypersexuality, binge eating, compulsive shopping) and leg oedema. Ergot agents carry fibrotic (valvular heart, pleuropulmonary) risks — rarely used now. Rotigotine patch suits non-adherent patients; apomorphine injection rescues "off" episodes in advanced disease.

MAO-B inhibitors

Selegiline, rasagiline (and safinamide) selectively inhibit monoamine oxidase B, reducing dopamine catabolism in the striatum. Mild benefit as early monotherapy or levodopa adjunct. Selegiline is given in the morning (insomnia at higher doses); avoid >10 mg/day, where MAO-A inhibition begins and tyramine ("cheese effect") hypertensive crisis becomes possible. Rasagiline 0.5–1 mg daily is once-daily and metabolically simpler.

COMT inhibitors

Entacapone (200 mg with each levodopa dose, max 8×/day) blocks peripheral catechol-O-methyltransferase, prolonging levodopa's action — a wearing-off adjunct only, with no effect alone (it does not cross the BBB meaningfully). Adverse effects mirror levodopa excess (dyskinesia, hallucinations) plus orange discoloration of urine. Tolcapone acts centrally but carries hepatotoxicity — monitor LFTs or avoid. Avoid combining entacapone with tolcapone.

Amantadine

An old antiviral with NMDA-antagonist and anticholinergic actions; increases dopamine release and blocks reuptake. Best uses: early mild disease and — most usefully today — levodopa-induced dyskinesias (100 mg 2–3×/day). Caution in renal impairment (renally cleared). Adverse effects: livedo reticularis, pedal oedema, confusion, hallucinations, QT prolongation.

Anticholinergics

Trihexyphenidyl (benzhexol), benztropine, orphenadrine block muscarinic receptors, rebalancing dopamine–acetylcholine. They help tremor and rigidity, not bradykinesia, and are the drugs for drug-induced parkinsonism when the causative dopamine blocker (e.g. haloperidol, metoclopramide) must continue. Adverse effects are the anticholinergic burden: confusion, hallucinations, urinary retention, constipation, tachycardia, blurred vision, dry mouth — avoid in the elderly, glaucoma and prostatism.

6 Drug Monographs: Doses, Indications & Safety

Each antiparkinsonian drug as a full monograph: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses — confirm against the current Uganda Clinical Guidelines before prescribing.

Levodopa/carbidopa (gold standard)

Scroll the table sideways on a smaller screen.

Levodopa + carbidopa — dopamine precursor + peripheral decarboxylase inhibitor
MechanismLevodopa crosses the blood–brain barrier (LAT1 transporter) and is converted to dopamine in the striatum; carbidopa blocks peripheral dopa-decarboxylase so more reaches the brain with fewer peripheral effects
IndicationsParkinson disease — most effective drug for all motor features (bradykinesia and rigidity respond best); all stages and ages
Adult doseStart carbidopa/levodopa 25/100 mg half–one tablet 2–3 times daily with food; titrate weekly to effect (usual 1 tablet 3–4 times daily); controlled-release for wearing-off
Paediatric doseNot applicable (rare dopamine-responsive dystonia uses are specialist)
Adverse effectsEarly: nausea, postural hypotension, somnolence/sudden sleep attacks. Late (years): wearing-off, dyskinesias, on-off phenomenon; hallucinations, impulse-control problems, psychosis
ContraindicationsPsychosis, narrow-angle glaucoma (caution), melanoma (historical caution), MAO-A inhibitors (stop ≥14 days)
InteractionsAntiemetics that block D2 (metoclopramide, prochlorperazine) and antipsychotics antagonise its effect — use domperidone/ondansetron instead; non-selective MAOIs (hypertensive crisis); iron and high-protein meals reduce absorption
Patient advice / monitoringNever stop abruptly — risk of parkinsonism-hyperpyrexia; take with low-protein meals; report hallucinations, sleep episodes and gambling/impulse changes; standing slowly (postural hypotension)

Pramipexole (dopamine D2/D3 agonist)

Scroll the table sideways on a smaller screen.

Pramipexole — non-ergot dopamine receptor agonist
MechanismDirect D2/D3 receptor stimulation (preferential D3 activity — links to its impulse-control effects)
IndicationsEarly Parkinson monotherapy (younger patients) to delay levodopa; adjunct to levodopa; restless legs syndrome
Adult doseStart 0.125 mg 3 times daily; increase weekly by 0.125–0.25 mg/dose; usual 0.5–1.5 mg/day (IR); extended-release start 0.375 mg once daily
Paediatric doseNot established
Adverse effectsNausea, orthostatic hypotension (first-dose), somnolence/sudden sleep attacks, leg oedema, dyskinesia as adjunct; impulse-control disorders (gambling, hypersexuality, binge eating)
ContraindicationsPsychosis; caution in elderly (cognitive sensitivity), renal impairment (dose-adjust)
InteractionsDopamine antagonists (antipsychotics, metoclopramide) reduce effect; CYP interactions are minor (renally cleared — cimetidine, amantadine raise levels)
Patient advice / monitoringTake the first dose at night, rise slowly; ask specifically about gambling, spending, sexual urges — patients rarely volunteer this; no driving if sleep attacks occur; renal dose review

Ropinirole (dopamine D2/D3 agonist)

Scroll the table sideways on a smaller screen.

Ropinirole — non-ergot dopamine receptor agonist
MechanismDirect D2/D3 receptor stimulation
IndicationsEarly Parkinson monotherapy or levodopa adjunct; restless legs syndrome
Adult doseStart 0.25 mg 3 times daily; increase weekly (0.25 → 1 → 2 → 3 mg/dose); usual 9–16 mg/day
Paediatric doseNot established
Adverse effectsNausea, somnolence/sleep attacks, orthostatic hypotension, leg oedema, impulse-control disorders, dyskinesia as adjunct
ContraindicationsAs pramipexole; caution in elderly
InteractionsCYP1A2 inhibitors (ciprofloxacin, fluvoxamine) raise levels; smokers (tobacco induces CYP1A2) may need more; dopamine antagonists oppose effect
Patient advice / monitoringSame vigilance as pramipexole for impulse control and sleep attacks; take with food to reduce nausea

Rotigotine (transdermal dopamine agonist)

Scroll the table sideways on a smaller screen.

Rotigotine — D2/D3 agonist, once-daily patch
MechanismDirect D2/D3 receptor stimulation delivered continuously through the skin — smooth, stable levels without peak-related dyskinesia
IndicationsEarly and advanced Parkinson disease; patients with swallowing difficulty or adherence problems; restless legs syndrome (lower doses); perioperative levodopa substitution
Adult doseStart 2 mg/24 h patch, increase weekly; usual 4–8 mg/24 h; RLS: 1–3 mg/24 h
Paediatric doseNot established
Adverse effectsApplication-site skin reactions, nausea, somnolence, hypotension, impulse-control disorders, hallucinations
ContraindicationsAs other agonists; avoid in psychosis
InteractionsFew CYP interactions (hepatic); dopamine antagonists oppose effect; heat increases absorption (sauna, fever)
Patient advice / monitoringApply at the same time daily to rotating sites; remove old patch; wash hands after; report skin reactions and impulse-control changes

Selegiline (MAO-B inhibitor)

Scroll the table sideways on a smaller screen.

Selegiline — selective monoamine oxidase B inhibitor
MechanismSelectively inhibits MAO-B → slows striatal dopamine breakdown; at >10 mg/day loses selectivity (tyramine risk begins)
IndicationsEarly Parkinson monotherapy (mild benefit); adjunct to levodopa for wearing-off
Adult dose5 mg twice daily (morning + midday) or 10 mg morning; avoid doses >10 mg/day; take in the morning to avoid insomnia
Paediatric doseNot established
Adverse effectsNausea, insomnia, dizziness, orthostatic hypotension; hallucinations, dyskinesia as adjunct; high doses: tyramine hypertensive crisis
ContraindicationsPheochromocytoma; caution with other serotonergic drugs (syndrome risk is low at selective doses)
InteractionsMeperidine/pethidine (serotonin syndrome — avoid); SSRIs/SNRIs (theoretical serotonin risk — use caution); carbamazepine, phenytoin, rifampicin lower levels
Patient advice / monitoringMorning dosing; avoid tyramine-heavy diets at higher doses; report insomnia, vivid dreams, hallucinations

Rasagiline (MAO-B inhibitor)

Scroll the table sideways on a smaller screen.

Rasagiline — selective MAO-B inhibitor
MechanismIrreversible, selective MAO-B inhibition → prolonged striatal dopamine availability
IndicationsEarly Parkinson monotherapy; adjunct to levodopa
Adult dose1 mg once daily (0.5 mg with moderate hepatic impairment or ciprofloxacin)
Paediatric doseNot established
Adverse effectsHeadache, nausea, postural hypotension, insomnia; dyskinesia and hallucinations as levodopa adjunct
ContraindicationsPheochromocytoma; hepatic impairment (avoid or halve)
InteractionsSympathomimetics, SSRIs/SNRIs (serotonin syndrome — caution, especially with mirtazapine or dextromethorphan-containing products); CYP1A2 inhibitors (ciprofloxacin) raise levels
Patient advice / monitoringOnce daily, any time but keep consistent; avoid pseudoephedrine-containing cold remedies; report headache or BP rise

Entacapone (COMT inhibitor)

Scroll the table sideways on a smaller screen.

Entacapone — peripheral catechol-O-methyltransferase inhibitor
MechanismBlocks peripheral COMT → prolongs levodopa's plasma half-life and smooths its CNS delivery; no effect alone
IndicationsAdjunct to levodopa for wearing-off (end-of-dose deterioration)
Adult dose200 mg with each levodopa dose (max 8 doses/day); dose reduction may be needed once dyskinesia appears
Paediatric doseNot established
Adverse effectsDyskinesia, hallucinations, nausea, diarrhoea, orange discoloration of urine (harmless), abdominal pain
ContraindicationsHepatic impairment (avoid — tolcapone alternative is worse); do not combine with tolcapone
InteractionsEnhances all levodopa effects (incl. toxicity); do not combine with non-selective MAOIs; iron salts chelate it (space doses)
Patient advice / monitoringOnly works alongside levodopa; orange urine is expected; report new or worse dyskinesia/hallucinations promptly — dose may need reduction

Amantadine (NMDA antagonist)

Scroll the table sideways on a smaller screen.

Amantadine — NMDA antagonist, anticholinergic, ↑ dopamine release
MechanismMultiple: NMDA-receptor antagonism (antidyskinetic effect), increases dopamine release and blocks its reuptake, anticholinergic activity
IndicationsEarly mild Parkinson disease; levodopa-induced dyskinesias (its most useful modern role); historically influenza A prophylaxis
Adult dose100 mg once–twice daily, usual 100 mg 2–3 times daily (max 400 mg/day)
Paediatric doseNot for Parkinson disease; influenza dosing is historical
Adverse effectsLivedo reticularis (harmless mottling), pedal oedema, confusion, hallucinations, insomnia, QT prolongation, seizures
ContraindicationsSevere renal impairment (renally cleared — reduce dose if eGFR low), psychosis, seizure disorders (caution)
InteractionsAnticholinergics compound its effects; diuretics (hydrochlorothiazide/triamterene) raise levels; alcohol worsens CNS effects
Patient advice / monitoringEarly in the day (insomnia); report mottled skin (harmless), ankle swelling, confusion; renal function review; do not stop flu-like after long use without advice

Trihexyphenidyl (benzhexol, anticholinergic)

Scroll the table sideways on a smaller screen.

Trihexyphenidyl — centrally acting muscarinic antagonist
MechanismBlocks central muscarinic receptors — rebalances the dopamine–acetylcholine ratio in the striatum
IndicationsTremor-predominant Parkinson disease (younger patients); drug-induced parkinsonism/extrapyramidal symptoms when the causative drug must continue; useful adjunct to haloperidol in psychosis care
Adult doseStart 1 mg once daily; increase by 2 mg every 3–5 days; usual 6–10 mg/day in divided doses (max 20 mg/day)
Paediatric dose>3 years (drug-induced EPS): 1–2 mg twice daily, specialist use
Adverse effectsConfusion and hallucinations, memory impairment, urinary retention, constipation, tachycardia, blurred vision, dry mouth, heat intolerance
ContraindicationsAvoid in the elderly, narrow-angle glaucoma, prostatism/urinary retention, tardive dyskinesia (worsens it), cognitive impairment
InteractionsAdditive anticholinergics (antihistamines, TCAs, antipsychotics) → delirium risk; reduces levodopa absorption; antagonises metoclopramide
Patient advice / monitoringExpect dry mouth (sips of water, sugar-free gum); avoid in hot weather/dehydration (heat stroke risk); report retention, confusion, palpitations

7 Master Comparison Table

Scroll the table sideways on a smaller screen.

Class / drugMechanismBest useSignature adverse effects
Levodopa + carbidopaDopamine precursor + peripheral decarboxylase inhibitorGold standard; bradykinesia, all stagesWearing-off, dyskinesia, nausea, hypotension, hallucinations; never stop abruptly
Dopamine agonists (pramipexole, ropinirole, rotigotine)D2/D3 receptor stimulationYounger patients; early monotherapy; RLS; adjunctImpulse-control disorders, sleep attacks, hypotension, leg oedema
MAO-B inhibitors (selegiline, rasagiline)↓ Dopamine breakdown (B)Early disease; wearing-off adjunctNausea, insomnia; tyramine risk at high selegiline dose
COMT inhibitors (entacapone)↓ Peripheral levodopa metabolismWearing-off adjunct onlyDyskinesia, hallucinations, orange urine; tolcapone: hepatotoxic
AmantadineNMDA antagonist; ↑ dopamine releaseMild disease; dyskinesiasLivedo reticularis, oedema, confusion, renal caution
Anticholinergics (trihexyphenidyl, benztropine)Muscarinic blockadeTremor; drug-induced parkinsonismConfusion, retention, tachycardia — avoid in elderly

8 Motor Fluctuations & Long-Term Complications

  • Wearing-off (end-of-dose) — predictable return of symptoms before the next dose as disease shortens levodopa's effect. Manage by fractionating doses, adding entacapone, using controlled-release formulations, or adding a dopamine agonist/MAO-B inhibitor.
  • On-off phenomenon — unpredictable, sudden switches between mobility ("on", often with dyskinesia) and immobility ("off"), unrelated to dosing times. Harder to treat: adjust administration, add apomorphine or consider deep brain stimulation (subthalamic nucleus).
  • Levodopa-induced dyskinesias — peak-dose choreiform movements after years of therapy, worse in young-onset patients. Reduce individual doses, add amantadine, or consider surgery.
  • Freezing — sudden, transient inability to move, often at doorways; responds poorly to drugs — visual cueing and physiotherapy help.

9 Prescribing Principles & Patient Safety

  • Start low, go slow — titrate to the minimum dose that restores function, not to abolish every symptom.
  • Individualise by age — younger patients start with agonists or MAO-B inhibitors to delay levodopa dyskinesia; older patients start levodopa (cognitive tolerance of agonists is poor).
  • Never stop abruptly — risk of parkinsonism-hyperpyrexia; taper and substitute.
  • Screen and counsel — warn about sleep attacks (driving), orthostatic hypotension (first-dose effect with agonists), impulse-control disorders (ask specifically), hallucinations and psychosis (dose reduction; quetiapine or clozapine if an antipsychotic is unavoidable — avoid D2 blockers).
  • Non-motor symptoms matter — constipation, depression, rapid eye movement sleep behaviour disorder, autonomic dysfunction; treat the patient, not the scan.

10 Special Situations

  • Drug-induced parkinsonism — D2 blockers: first-generation antipsychotics (haloperidol, fluphenazine), metoclopramide, prochlorperazine, reserpine, tetrabenazine. Stop the culprit; if it must continue (psychosis), switch to low-D2 agents (quetiapine, clozapine) and treat with anticholinergics or amantadine. Domperidone is preferred as an antiemetic in PD because it does not cross the BBB.
  • Perioperative care — continue levodopa through nil-by-mouth periods (NG or transdermal rotigotine); abrupt omission precipitates crisis.
  • Psychosis in PD — reduce Parkinson drugs in reverse order of potency (anticholinergic → agonist → MAO-B/COMT → levodopa); if an antipsychotic is essential, use quetiapine or clozapine (minimal D2 blockade).
  • Advanced options — deep brain stimulation, levodopa-carbidopa intestinal gel, apomorphine infusion for refractory fluctuations.

11 Viva & Exam Points

  • Gold standard — levodopa + carbidopa; bradykinesia/rigidity respond best, tremor least.
  • Carbidopa — peripheral decarboxylase inhibitor; does not cross BBB.
  • Agonists — impulse-control disorders; young patients; rotigotine patch.
  • Entacapone — COMT inhibitor, wearing-off adjunct; orange urine. Tolcapone — hepatotoxic.
  • Selegiline — MAO-B; morning dosing; avoid >10 mg (tyramine crisis).
  • Amantadine — dyskinesias; livedo reticularis; renal caution.
  • Anticholinergics — tremor and drug-induced parkinsonism; avoid elderly.
  • Never stop levodopa abruptly — parkinsonism-hyperpyrexia.

12 References

For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top